
|Articles|September 1, 2002
- Pharmaceutical Executive-09-01-2002
Top European Trial Sponsors
A CenterWatch survey of 545 European clinical trial investigators named the best pharma companies to work with in clinical development.
Advertisement
A CenterWatch survey of 545 European clinical trial investigators named the best pharma companies to work with in clinical development. Bayer, Lilly, Pharmacia, and AstraZeneca were listed as the top sponsors for their attentive study monitoring, realistic protocol design, and improved staff training. The survey rated more than 30 European pharma companies.
Articles in this issue
about 24 years ago
Pharmaceutical Innovation Under Attackabout 24 years ago
More Statins = Fewer Heart Attacksabout 24 years ago
When Worlds Collideabout 24 years ago
Novo Nordisk Cancels Clinical Trialsabout 24 years ago
Dutch Government Just Says Noabout 24 years ago
Lilly Marketers Cross the Lineabout 24 years ago
Spending Hits a Wallabout 24 years ago
Strangers in the Shadowsabout 24 years ago
Plants and Patentsabout 24 years ago
Industry Audit & Companies of the YearAdvertisement
Related to this article

Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.

Foghorn Therapeutics and Eli Lilly are discontinuing their SMARCA2 degrader Fhd-909 after Phase I data fell short on efficacy.

Novartis licenses Abogen's mRNA-encoded CD19xCD3 T-cell engager, while AstraZeneca and Daiichi Sankyo partner with Summit Therapeutics.

CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference.

Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.

FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
FDA has expanded Camzyos's approval to treat symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients as young as 12.

Regeneron and Sanofi are expanding their two-decade antibody alliance to co-develop four new long-acting immunology antibodies in a deal worth up to $8 billion.
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
2
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
3
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
4
FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
5

